Serostim market forecast points to growth through 2035
The Business Research Company says the Serostim market is set to expand through 2035, driven by rising HIV/AIDS diagnoses, broader chronic disease burden and growing demand for therapies that address wasting and loss of lean mass. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.
Why it matters: - Serostim is positioned as a treatment for HIV-associated wasting and cachexia, a condition tied to severe weight loss and loss of lean body mass. - Market growth matters because demand is tied to rising HIV/AIDS cases, wider chronic disease burden and more focus on therapies that improve quality of life. - The forecast period runs through 2035, giving investors and healthcare providers a long runway to track adoption trends.
What happened: - The Business Research Company published its Serostim Global Market Report 2026, covering market size, trends and forecasts from 2026 to 2035. - The report says the Serostim market has historically grown on the back of recombinant somatropin formulations and improved treatment strategies for HIV-associated wasting. - The report also points to expanding antiretroviral therapy access, stronger clinical awareness of cachexia and growth in home-care models.
The details: - Serostim is a recombinant human growth hormone, or somatropin, designed to combat HIV-associated wasting. - The treatment is intended to help patients gain body weight, increase lean body mass and improve physical endurance. - The report identifies rising HIV/AIDS incidence as a major market driver. - In October 2024, the UK Health Security Agency reported 6,008 new HIV diagnoses in England in 2023, up from 3,975 in 2022. - The report links market growth to other target diseases as well, including tuberculosis. - The US Centers for Disease Control and Prevention reported tuberculosis cases rose from 8,320 in 2022 to 9,615 in 2023. - The report also ties demand to chronic diseases such as diabetes, heart disease and asthma, which are becoming more common alongside sedentary lifestyles. - The Australian Institute of Health and Welfare said in July 2024 that chronic diseases accounted for 78% of the total fatal burden. - Regionally, North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report also covers Western Europe, Eastern Europe, South America, the Middle East and Africa. - New report features include market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, market hotspot infographics and updated graphics and tables. - The report includes a free sample and the full market report.
Between the lines: - The market thesis is not just about HIV treatment volume. - The report suggests Serostim’s opportunity is expanding because healthcare systems are paying more attention to wasting, metabolic support and adjunctive care. - The emphasis on long-acting hormone formulations and monitoring tools suggests the category may be moving toward more convenient and more closely managed treatment models.
What's next: - The report expects growth to be supported by broader adoption of adjunctive HIV therapies and stronger home-care delivery models. - Demand may also increase as more patients are diagnosed earlier and as healthcare providers expand supportive care for chronic and wasting-related conditions. - The company's 2026 report set adds future-trend analysis and forecasting tools that signal continued attention to the segment.
Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.
Sign up for:
Market Forecast Analysis
The daily local news briefing you can trust. Every day. Subscribe now.
Check Your Email!
We sent a one-time activation link to: .
Confirm it's you by clicking the email link.
If the email is not in your inbox, check spam or try again.
Welcome back!
is already signed up. Check your inbox for updates.